Literature DB >> 9659357

New ideas on the pathophysiology and treatment of lung disease.

D F Rogers1, G J Laurent.   

Abstract

There is a continuing need for development of new treatments for lung disease. Basic scientific investigations are identifying novel targets for the development of new approaches to therapy of a range of respiratory conditions. Coupled with the advances in technology being harnessed by the pharmaceutical and biotechnological industries, there is now an impressive range of potential treatments including gene therapy, not just for cystic fibrosis but also for a range of inflammatory lung conditions, anti-cytokine and anti-adhesion molecule approaches, and targeting of intracellular signal transduction pathways including cyclic AMP metabolism, tyrosine kinases and MAP kinases. "Old" molecules such as heparin and secretory leukoprotease inhibitor (SLPI) are demonstrating new beneficial activities. Simple molecules such as nitric oxide (NO) gas may be involved in the pathophysiology of different airway conditions. It is an exciting time for respiratory science and a time for optimism for those seeking new approaches to the treatment of lung diseases.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9659357      PMCID: PMC1745171          DOI: 10.1136/thx.53.3.200

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  21 in total

Review 1.  Phosphodiesterase inhibitors: Lily the Pink's medicinal compound for asthma?

Authors:  G Dent; M A Giembycz
Journal:  Thorax       Date:  1996-06       Impact factor: 9.139

2.  In vivo veritas: the continuing importance of discoveries in complex biosystems.

Authors:  C G Persson
Journal:  Thorax       Date:  1996-04       Impact factor: 9.139

3.  Cell signalling in pulmonary vascular cells: do not shoot the messenger!

Authors:  P H Scott; A J Peacock
Journal:  Thorax       Date:  1996-08       Impact factor: 9.139

Review 4.  Gene therapy for cystic fibrosis: which postman, which box?

Authors:  P G Middleton; E W Alton
Journal:  Thorax       Date:  1998-03       Impact factor: 9.139

5.  Airway epithelial repair: breathtakingly quick and multipotentially pathogenic.

Authors:  J S Erjefält; C G Persson
Journal:  Thorax       Date:  1997-11       Impact factor: 9.139

Review 6.  Scorpion venoms: taking the sting out of lung disease.

Authors:  D F Rogers
Journal:  Thorax       Date:  1996-05       Impact factor: 9.139

Review 7.  Function at the junction: dynamic interactions between lung cells and extracellular matrix.

Authors:  J R Spurzem
Journal:  Thorax       Date:  1996-09       Impact factor: 9.139

Review 8.  Pulmonary hypertension: NO therapy?

Authors:  S Adnot; B Raffestin
Journal:  Thorax       Date:  1996-07       Impact factor: 9.139

Review 9.  NO or no NO in asthma?

Authors:  P J Barnes
Journal:  Thorax       Date:  1996-02       Impact factor: 9.139

10.  Lymphocyte dynamics: caution in interpreting BAL numbers.

Authors:  R Pabst; T Tschernig
Journal:  Thorax       Date:  1997-12       Impact factor: 9.139

View more
  2 in total

Review 1.  Novel drugs for treating asthma.

Authors:  T T Hansel; P J Barnes
Journal:  Curr Allergy Asthma Rep       Date:  2001-03       Impact factor: 4.806

Review 2.  Science review: Redox and oxygen-sensitive transcription factors in the regulation of oxidant-mediated lung injury: role for nuclear factor-kappaB.

Authors:  John J Haddad
Journal:  Crit Care       Date:  2002-10-14       Impact factor: 9.097

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.